Review

The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis

Zhenwei Yang\textsuperscript{a,b,1}, Jialong Liu\textsuperscript{a,b,1}, Yunjiao Zhou\textsuperscript{a,b}, Xixian Zhao\textsuperscript{a,b}, Qiu Zhao\textsuperscript{a,b}, Jing Liu\textsuperscript{a,b,*}

\textsuperscript{a} Department of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China
\textsuperscript{b} Hubei Clinical Center and Key Laboratory of Intestinal and Colorectal Diseases, Wuhan 430071, China

**ARTICLE INFO**

Article history: Accepted 31 March 2020 Available online 10 April 2020

Keywords: Coronavirus COVID-19 corticosteroid treatment Meta-analysis

**SUMMARY**

Objectives: An outbreak of novel coronavirus in 2019 threatens the health of people, and there is no proven pharmacological treatment. Although corticosteroids were widely used during outbreaks of severe acute respiratory syndrome and Middle East respiratory syndrome, their efficacy remains highly controversial. We aimed to further evaluate the influence of corticosteroids on patients with coronavirus infection.

Methods: We conducted a comprehensive search of literature published in PubMed, Embase, Cochrane library, and China National Knowledge Infrastructure (CNKI) from January 1, 2002 to March 15, 2020. All statistical analyses in this study were performed on stata14.0.

Results: A total of 5270 patients from 15 studies were included in this meta-analysis. The result indicated that critical patients were more likely to require corticosteroids therapy (risk ratio [RR] = 1.56, 95% confidence interval [CI] = 1.28–1.90, \(P = 0.001 \)). However, corticosteroid treatment was associated with higher mortality (RR = 2.11, 95%CI = 1.13–3.94, \(P = 0.019 \)), longer length of stay (weighted mean difference [WMD] = 6.31, 95%CI = 5.26–7.37, \(P < 0.001 \)), a higher rate of bacterial infection (RR = 2.08, 95%CI = 1.54–2.81, \(P = 0.001 \)), and hypokalemia (RR = 2.21, 95%CI = 1.07–4.55, \(P = 0.032 \)) but not hyperglycemia (RR = 1.37, 95%CI = 0.68–2.76, \(P = 0.376 \)) or hypocalcemia (RR = 1.35, 95%CI = 0.77–2.37, \(P = 0.302 \)).

Conclusions: Patients with severe conditions are more likely to require corticosteroids. Corticosteroid use is associated with increased mortality in patients with coronavirus pneumonia.

© 2020 Published by Elsevier Ltd on behalf of The British Infection Association.

**INTRODUCTION**

In December 2019, the pneumonia caused by a new coronavirus spread in Wuhan, China. Unbiased sequencing of samples from patients with pneumonia reveals a previously unknown type of beta-coronavirus which is similar to the severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV).\textsuperscript{1} The causative agent was named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by Coronavirus Study Group, and the disease it caused was named coronavirus disease 2019 (COVID-19) by the World Health Organization (WHO).\textsuperscript{2,3}

SARS-CoV-2 is a new type of highly diverse enveloped positive single stranded RNA virus, which can cause a range of symptoms including self-reported fever, fatigue, dry cough, myalgia, and difficulty breathing.\textsuperscript{4} There is evidence that the transmission pattern of SARS-CoV-2 is human-to-human which is spread by respiratory droplets caused by coughing or sneezing.\textsuperscript{5,6} As of March 19, there are now more than 200,000 COVID-19 cases and more than 8,000 deaths in the world.\textsuperscript{7} Nevertheless, there is no vaccine or antiviral treatment for human coronavirus. Therefore, it is crucial to determine the drug treatment plan as soon as possible to deal with the outbreak of COVID-19.\textsuperscript{8}

Corticosteroids have a good inhibitory effect on inflammatory factors and are often used as an auxiliary treatment for viral pneumonia. The main anti-inflammatory effect of glucocorticoids is to inhibit a large number of pro-inflammatory genes that encode cytokines, chemokines, cell adhesion molecules, inflammatory enzymes, and receptors to address the inflammatory process and restore homeostasis.\textsuperscript{9} However, the results of clinical studies on the role of corticosteroids remain controversial. A retrospective study showed that the vast majority of SARS patients received satisfactory results from the use of corticosteroids.\textsuperscript{10} But in a retrospective observational study of MERS patients, the result showed that patients who were given corticosteroids were more likely to require

---

* Corresponding author.
E-mail address: liujing_GH@whu.edu.cn (J. Liu).

\textsuperscript{1} The authors contributed equally to this work.
mechanical ventilation, vasopressors, and renal replacement therapy. Therefore, we performed this meta-analysis to identify the roles of corticosteroids in patients with coronavirus.

Methods

Search strategies

Literature published in PubMed, Embase, Cochrane library and China National Knowledge Infrastructure (CNKI) from January 1, 2002 to March 15, 2020 was searched by combining the following keywords: "SARS" or "coronavirus" or "severe acute respiratory syndrome" or "Middle East respiratory syndrome coronavirus" or "MERS viruses" or "MERS-CoV" or "novel coronavirus" or "2019-nCoV" or "COVID-19" or "SARS CoV-2" and "steroid" or "corticosteroid" or "prednisolone" or "prednisone" or "dexamethasone" or "cortisol" or "hydrocortisone" or "glucocorticoid" or "methylprednisolone" without limitations on either the publication type or language. In addition, the references listed in each identified article were also screened and manually searched to make the results more comprehensive. The work was done independently by two authors (Zhenwei Yang and Jialong Liu). Disagreements were resolved by a third investigator (Yunjiao Zhou).

Inclusion and exclusion criteria

The inclusion criteria in this meta-analysis were as follows: (1) subjects in each study were patients with coronavirus infection; (2) the patients were divided into the experimental group using corticosteroids and the control group not using corticosteroids; (3) the outcomes included the use of corticosteroids in critical and non-critical patients, mortality, length of stay (LOS) and adverse reactions to corticosteroids. Exclusion criteria: (1) the same patients were enrolled in different articles; (2) commentaries, editorials, case reports, letters and family-based studies; and (3) patients in studies were under 18 years old.

Data extraction

The two researchers (Zhenwei Yang and Jialong Liu) who performed the inclusion and exclusion of the literature also independently extracted data from the included studies. Differences were resolved with a third investigator (Xixian Zhao) or by consensus. We extracted the following variables: the authors, the publication year, the study design, viral type, population, treatment details (including corticosteroid use, types and doses of corticosteroids, and other treatments), and outcome measures such as the use of corticosteroids in critical and non-critical patients, mortality, LOS and adverse reactions to corticosteroids (including bacterial infection, hyperglycemia, hypocalcemia and hypokalemia).

Quality assessment

We used the Newcastle-Ottawa scale (NOS), which includes patient selection, study comparability and outcome assessment three components, to evaluate the quality of the original study. The work was done by two authors (Zhenwei Yang and Jialong Liu) and agreed upon through discussion.

Statistical analysis

All statistical analyses in this study were performed on stata14.0 (Stata, College Station, TX, USA). For dichotomized data, we calculated the risk ratio (RR) and the 95% confidence interval (CI), while for continuous data, we calculated the weighted mean difference (WMD) and the 95% CI. Heterogeneity among the studies was assessed by the Chi squared and I² tests. A random-effects model was used when either P<0.10 or I²>50% defined significant heterogeneity across the articles. Otherwise, the fixed-effects model was used. We carried out a sensitivity analysis on the stability of the combined results. In addition, we also performed a subgroup analysis by virus type to explore the source of heterogeneity. Publication bias was assessed by funnel plots.

Results

Search results

As shown in Fig. 1, the total number of records initially determined based on the search strategy was 1685. After removing 412 duplicates, we deleted another 1203 articles by reading the title and abstract of the article. We eliminated 55 articles by reading the full-text articles of the remaining 70 studies, four of which enrolled the same patients, two of which were non-adult patients, and 49 of which did not have a control group not using corticosteroids. Finally, there were 15 articles included in our meta-analysis.

Study characteristics

5270 patients from 15 articles were included in our systematic review and meta-analysis. Due to one article did not give the number of people treated with corticosteroids, among the remaining 14 articles, 3176 patients were treated with corticosteroids and 1780 were treated with non-corticosteroids. Among the 15 literatures, 7 are in English and 8 are in Chinese. Eleven studies included

Fig. 1. Flow chart of literature search and selection of studies.
patients with SARS-CoV infection, two included patients with MERS-CoV infection, and the remaining two included patients with SARS-CoV-2 infection. There were 7 articles describing the use of corticosteroids in critical and non-critical patients,5,13,15,16,19,22,23 9 articles recorded the mortality,10,11,14–18,20,22 three studies reported the LOS,11,18,22 2 articles described the adverse reactions to corticosteroids.21,24 In addition, all studies had NOS scores ≥6. The details of each included study are presented in Table 1.

The use of corticosteroids in critical and non-critical patients

The results showed that patients with severe conditions were more likely to require corticosteroids therapy (RR = 1.56, 95% CI = 1.28–1.90, P < 0.001; Fig. 2). There was significant heterogeneity among the studies (I² = 90.2%, P < 0.001), the random effects model was adopted. Similar results were also observed in the subgroup analysis of patients with SARS-CoV-2 infection (RR = 2.36, 95%CI = 1.31–4.28, P = 0.004, I² = 29.1%, P = 0.235) and patients with SARS-CoV infection (RR = 1.46, 95%CI = 1.18–1.80, P < 0.001, I² = 92.7%, P < 0.001). Sensitivity analysis showed that the result was stable.

Mortality

The pooled RR from the nine studies revealed that the mortality was higher in patients who received corticosteroids therapy (RR = 2.11, 95%CI = 1.13–3.94, P = 0.019, I² = 80.9%, P < 0.001; Fig. 3). When we performed subgroup analysis, we found that the mortality of neither SARS-CoV (RR = 2.56, 95%CI = 0.99–6.63, P = 0.053, I² = 77.4%, P = 0.001) nor MERS-CoV (RR = 2.06, 95%CI = 0.66–6.44, P = 0.213, I² = 89.4%, P = 0.002) was correlated with corticosteroids therapy. Sensitivity analysis showed that the result was not stable. When we excluded a study,16 the result was different from the previous conclusion.

LOS

LOS was longer in the corticosteroid group (WMD = 6.31, 95%CI = 5.26–7.37, P < 0.001, I² = 18.3%, P = 0.361; Fig. 4), and the same result was found in the subgroup analysis of patients with SARS-CoV infection (WMD = 6.34, 95%CI = 5.24–7.44, P < 0.001, I² = 50.3%, P = 0.156).

Adverse reactions to corticosteroids

As shown in Table 2, patients treated with corticosteroids were more likely to have adverse reactions such as bacterial infection (RR = 2.08, 95%CI = 1.54–2.81, P < 0.001, I² = 8.0%, P = 0.926) and hypokalemia (RR = 2.21, 95%CI = 1.07–4.55, P = 0.032, I² = 53.1%, P = 0.104). However, there was no relationship between corticosteroid therapy and the development of hyperglycemia (RR = 1.37, 95%CI = 0.68–2.76, P = 0.376, I² = 74.2%, P = 0.049) or hypocalcemia (RR = 1.35, 95%CI = 0.77–2.37, P = 0.302, I² = 80.4%, P = 0.024).

![Table 1](image1.png)

**Table 1.** Characteristics of Studies of Corticosteroids Use in SARS-CoV and MERS-CoV Patients.

| Study ID | RR (95% CI) | Weight |
|----------|-------------|---------|
| Wang D (2020) | 2.05 (1.47, 2.85) | 12.41 |
| Huang C (2020) | 4.31 (1.27, 14.59) | 2.31 |
| Subtotal (I-squared = 29.1%, p = 0.235) | 2.36 (1.31, 4.26) | 14.72 |
| Chen RC (2006) | 1.35 (1.18, 1.54) | 17.59 |
| Ding K (2005) | 1.07 (0.97, 1.17) | 18.26 |
| Wang R (2004) | 1.64 (1.51, 1.78) | 18.44 |
| Qin YY (2003) | 1.71 (1.33, 2.20) | 14.60 |
| Jia WD (2009) | 1.73 (1.44, 2.08) | 16.39 |
| Subtotal (I-squared = 92.7%, p = 0.000) | 1.46 (1.18, 1.80) | 85.28 |
| Overall (I-squared = 90.2%, p = 0.000) | 1.56 (1.28, 1.90) | 100.00 |

Fig. 2. The use of corticosteroids in critical and non-critical patients.
| Reference | Year | Country | Viral type | Study design | Study N | Corticosteroids | Dose | Other treatments | Outcomes Measured | NOS score |
|-----------|------|---------|------------|-------------|---------|----------------|------|-----------------|------------------|-----------|
| Wang D\(^1\) | 2020 | China   | SARS-CoV-2 | Retrospective | 138     | ICU:26 Non-ICU:36 | NR   | Antiviral therapy, antibacterial therapy, ECMO | The use of corticosteroids | 7         |
| Alfaraj SH\(^1\) | 2019 | Saudi Arabia | MERS-CoV | Retrospective | 314     | majority of patients | NR   | Plasmapheresis, immunoglobulin, ECMO, CRRT, interferon, ribavirin | Mortality | 6         |
| Arabi YM\(^1\) | 2018 | Saudi Arabia | MERS-CoV | Retrospective | 309     | 151 | The median of the maximum daily hydrocortisone-equivalent dose was 300.0 mg, with a median duration of 7.0 days. Hydrocortisone (Group HC), mean daily dose: 695mg Methylprednisolone (Group MP), mean daily dose: 540mg Pulsed methylprednisolone (Group Pulse), mean daily dose: 924mg Prednisolone (Group P), mean daily dose: 468mg | Mortality, LOS | 9         |
| Yam LY\(^1\) | 2007 | Hong Kong, China | SARS-CoV | Retrospective | 1287   | Hydrocortisone: 621 Methylprednisolone: 177 Pulsed methylprednisolone: 220 Prednisolone: 170 | NR   | Antiviral therapy, interferon, CRRT, ECMO Ribavirin | Mortality | 9         |
| Chen RC\(^1\) | 2006 | China   | SARS-CoV | Retrospective | 401     | Noncritical: 147 Critical: 121 | 147 noncritical patients received corticosteroids (mean daily dose, 105.3 ± 86.1 mg); 121 critical patients received corticosteroids at a mean daily dose of 131.5 ± 102.3 mg. | Mortality, the use of corticosteroids | 9         |
| Auyeung TW\(^1\) | 2005 | Hong Kong, China | SARS-CoV | Retrospective | 78      | Corticosteroid therapy: n=66 | NR   | Antiviral therapy, antibiotic therapy, immunoglobulin, convalescence serum | Mortality | 9         |
| Huang C\(^1\) | 2020 | China   | SARS-CoV-2 | Retrospective | 41      | ICU care: 6 No ICU care: 3 | NR   | Antiviral therapy, antibiotic therapy, CRRT | The use of corticosteroids | 7         |
| Jia WD\(^1\|5\) | 2009 | China   | SARS-CoV | Retrospective | 225     | 134 | The initial dose of corticosteroids were divided into 5 groups: 1–79 mg/d, 80–159 mg/d, 160–239 m/d, 240–319 mg/d, ≥320 mg/d | NR | Mortality, the use of corticosteroids | 8         |
| Ding K\(^1\) | 2005 | China   | SARS-CoV | Retrospective | 409     | Critical patients: 99 Non-critical patients: 234 | II Group: methylprednisolone= 80mg/d; III Group:80mg< methylprednisolone≤ 160mg/d; IV Group: methylprednisolone > 160mg/d | NR | The use of corticosteroids | 6         |
| Wang P\(^1\) | 2005 | China   | SARS-CoV | Retrospective | 294     | Group b: 192 Group c: 53 | NR | Antibacterial therapy, antiviral therapy | Mortality, LOS | 9         |
| Xu Y\(^1\) | 2005 | China   | SARS-CoV | Retrospective | 453     | 313 | The initial dose of corticosteroids were divided into 3 groups: 40 ~ 80 mg/d, 120 ~ 160 mg/d, and >200mg/d. | NR | Mortality, LOS | 7         |
| Wang R\(^2\) | 2004 | China   | SARS-CoV | Retrospective | 680     | 41 | NR | Antibacterial therapy, antiviral therapy | Mortality, the use of corticosteroids | 8         |
| Wang YQ\(^1\) | 2004 | China   | SARS-CoV | Retrospective | 460     | 344 | Intraavenous drops of methylprednisolone (40–320mg/d) | Adverse reactions to corticosteroids | 9         |
| He R\(^1\) | 2013 | China   | SARS-CoV | Retrospective | 98      | 57 | The initial dose of corticosteroids were divided into 3 groups: <160 mg/d, 160 ~ 320 mg/d, and ≥320mg/d. | NR | Adverse reactions to corticosteroids | 7         |
| Qin YY\(^2\) | 2003 | China   | SARS-CoV | Retrospective | 83      | 64 | Intraavenous methylprednisolone (40 ~ 320 mg/d), with an average of 17.3±9.0 d. | Adverse reactions to corticosteroids | 7         |

Note: ICU, intensive care unit; ECMO, extracorporeal membrane oxygenation; CRRT, continuous renal replacement therapy; CPAP, continuous positive airway pressure; NR, not report.
Fig. 3. Effect of corticosteroids on mortality.

Table 2
Adverse reactions to corticosteroid therapy.

| Adverse reactions to corticosteroids | Number of studies | Pooled RR (95% CI) | P Value | Heterogeneity | Effect model |
|-------------------------------------|-------------------|--------------------|---------|---------------|--------------|
| Bacterial infection                 | 2                 | 2.08 (1.54-2.81)   | <0.001 | 0.0           | Fixed        |
| Hyperglycemia                       | 2                 | 1.37 (0.68-2.76)   | 0.376  | 74.2          | Random       |
| Hypocalcemia                        | 2                 | 1.35 (0.77-2.37)   | 0.302  | 80.4          | Random       |
| Hypokalemia                         | 2                 | 2.21 (1.07-4.55)   | 0.032  | 53.1          | Random       |

Note: RR, risk ratio.

Publication bias

We examined the publication bias of the included literature on the use of corticosteroids in critical and non-critical patients and mortality. Funnel plots showed that there was no publication bias on the use of corticosteroids in critical and non-critical patients (Fig. 5A), while there might be publication bias on mortality (Fig. 5B).

Discussion

As SARS-CoV-2 is an emerging virus, there is no effective antiviral treatment at present. COVID-19 patients were mainly treated with symptomatic therapy. In clinic, corticosteroids are widely used in symptomatic treatment of severe pneumonia. However, there has been considerable controversy as to whether COVID-19 patients should be treated with corticosteroids. Russell and colleagues recommend that corticosteroids should not be used in SARS-CoV-2-induced lung injury or shock outside of a clinical trial.25 But a team of front-line physicians from China had a different perspective, they recommended short courses of corticosteroids at low-to-moderate dose, used prudently, for critical patients with COVID-19 pneumonia.26 So it is very important to provide evidence for corticosteroid treatment of in patients with coronavirus.

In this systematic review and meta-analysis, the result indicated that patients with severe conditions were more likely to require corticosteroids therapy. The similar results were also observed in the subgroup of patients with SARS-CoV-2 infection and patients with SARS-CoV infection. A study showed that the concentrations of cytokines (such as interleukin 7 [IL7], IL8, IL9, IL10 and so on) in serum in the COVID-19 patients were higher than in healthy
adults. In addition, cytokines (such as IL2, IL7, IL10 and so on) concentrations in intensive care unit (ICU) patients were higher than non-ICU patients. These revealed that patients with COVID-19 were usually accompanied by increased immune factors and inflammatory responses, and the concentrations of immune factors were associated with the severity of the disease. Further autopsy revealed bilateral diffuse alveolar injury with fibrous mucinous exudate and interstitial mononuclear inflammatory infiltration dominated by lymphocytes, which were very similar to SARS-CoV and MERS-CoV infections. As we all known, corticosteroids do not directly inhibit virus replication, their main role is anti-inflammatory and suppress immune response. In the early stage of inflammation, glucocorticoids reduce capillary dilatation, inflammatory cell exudation, leukocyte infiltration, and phagocytosis. In the late stage, glucocorticoids can inhibit the excessive proliferation of capillaries and fibroblasts. Furthermore, by binding to their receptors, glucocorticoids inhibit nuclear transcription factor-κB (NF-κB) signaling and further inhibit the transcription and translation of inflammatory factors. These explained why corticosteroids therapy was more needed in severely ill patients with coronavirus infection.

Our analysis demonstrated that patients treated with corticosteroids had a higher mortality rate, and longer LOS. There might be multiple mechanisms that contributed to these outcomes. There is a study shows that glucocorticoids inhibit the production of IL-2 and interferon-γ (IFN-γ) in T lymphocytes, shift T cell responses from the Th1 to the Th2 type, induce programmed cell death in a variety of different immunologically relevant cells, including immature T and B cell precursors and mature T cells. Another study find that preexisting CD4+ T cells are associated with lower viral shedding and less severe disease. There is evidence that the use of corticosteroids may lead to prolonged removal of viral RNA from the airways, blood, and feces of patients, resulting in longer hospital stays, and ultimately increasing the risk of mortality. In addition, our analysis found that patients receiving corticosteroid therapy were more likely to develop bacterial infection due to immunosuppression. This could make the disease worse and lead to death. We also performed subgroup analysis, the result indicated that the mortality of neither SARS-CoV nor MERS-CoV was associated with corticosteroids therapy. Sensitivity analysis showed that the use of corticosteroids was not associated with mortality when we excluded a study. Therefore, we need to treat this result with caution.

Our analysis found that patients receiving corticosteroids therapy might cause some serious adverse reactions such as bacterial infection and hypokalemia. However, only two studies in our analysis reported data on adverse reactions to corticosteroids, bias might have occurred due to the limited number of patients. There were several meta-analyses explored the role of corticosteroids in viral pneumonia, most of which shown adverse consequences. In a meta-analysis of corticosteroid use in patients with SARS, a total of 29 studies on corticosteroids were included, of which 25 were inconclusive, and only 4 provided conclusive data on the harms of corticosteroids. In a meta-analysis of corticosteroid use in patients with influenza pneumonia, the results showed that compared with placebo, corticosteroids were associated with higher mortality, longer ICU LOS, and a higher rate of

![Table: Effect of corticosteroids on length of stay (LOS).](image)

| Study     | MERS-CoV                          | SARS-CoV                          |
|-----------|-----------------------------------|-----------------------------------|
| ID        |                                   |                                   |
| WMD (95% CI) | Weight                           | WMD (95% CI) | Weight |
| Arabi YM (2018) | 6.00 (2.10, 9.90) | 7.36 |
| Subtotal (I-squared = .%, p = .) | 6.00 (2.10, 9.90) | 7.36 |
| Wang P (2005) | 9.00 (5.16, 12.84) | 7.57 |
| Wang R (2004) | 6.10 (4.95, 7.25) | 85.07 |
| Subtotal (I-squared = 50.3%, p = 0.156) | 6.34 (5.24, 7.44) | 92.64 |
| Heterogeneity between groups: p = 0.870 |                           |                                   |
| Overall (I-squared = 1.8%, p = 0.361) | 6.31 (5.26, 7.37) | 100.00 |

**Fig. 4.** Effect of corticosteroids on length of stay (LOS).
secondary infection but not mechanical ventilation days. In addition, a meta-analysis included ten studies with 1137 recovered SARS patients showed that patients who received higher cumulative doses and longer treatment durations of steroids were more likely to develop osteonecrosis. These meta-analyses indicated that patients with coronavirus pneumonia could not benefit from corticosteroid treatment.

However, there are some limitations in this meta-analysis. First, most of the included studies are retrospective cohort studies, historical control studies, etc., with a low level of evidence and a lack of randomized controlled trials with optimized design. Second, there is no uniform standard for the time and dosage of hormones used in various studies. Third, the effects of corticosteroids may be influenced by other therapeutic options, such as antiviral drugs. Finally, due to the rapid evolution of the SARS-CoV-2 situation, some studies have not been published, while other developments are not intended to be reported for reasons of confidentiality, which will lead to publication bias.

Conclusions

Patients with severe conditions were more likely to require corticosteroids. Corticosteroids could lead to higher mortality, longer LOS, a higher rate of bacterial infection and hypokalemia. Therefore, corticosteroid should be used with caution in the treatment of COVID-19 patients: corticosteroids are not recommended for patients with mild conditions, and moderate corticosteroids can be used in patients with severe conditions to suppress the immune response and reduce symptoms. Nevertheless, more multicenter clinical trials are needed to further verify this conclusion.

Contributors

All the authors designed the study. Zhenwei Yang, Jialong Liu and Yunjiao Zhou designed the literature search and searched the articles. Zhenwei Yang, Jialong Liu and Xixian Zhao contributed to the data extraction process. All the authors analysed the data. Zhenwei Yang wrote the first draft of article. All the authors revised the article and approved the final version.

Declaration of Competing Interest

No authors have competing interests in this research.

Funding

The work was supported by a research grant from the National Natural Science Foundation of China (Jing Liu, grant no. 81472735) and the Wuhan University (Jing Liu, grant no. 2042019K0206).

Acknowledgments

None.

References

1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020 Feb 20;382(8):727–33 PubMed PMID: 31978945. Epub 2020/01/25. eng.
2. Gorbachenya A.E., Baker S.C., Baric R.S., de Groot R.J., Drosten C., Gulyaeva A.A., et al. Severe acute respiratory syndrome-related coronavirus: The species and its viruses – a statement of the Coronavirus Study Group. 2020;2020.02.07.3937462.
3. WHO. WHO Director-General’s remarks at the media briefing on 2019-nCoV on 11 February 2020. Available from: https://www.who.int/dgh/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020.
4. He F, Deng Y, Li W. Coronavirus disease 2019 (COVID-19): what we know? J Med Virol. 2020 Mar 14. PubMed PMID: 32170865. Epub 2020/03/15. eng.
5. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, England) 2020 Feb 15;395(10223):497–506 PubMed PMID: 31986264. Epub 2020/01/28. eng.
6. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet (London, England) 2020 Feb 15;395(10223):513–23 PubMed PMID: 31986261. Epub 2020/01/28. eng.
7. WHO. WHO Director-General’s opening remarks at the Mission briefing on COVID-19 - 19 March 2020. Available from: https://www.who.int/dgh/speeches/detail/who-director-general-s-opening-remarks-at-the-mission-briefing-on-covid-19—19-march-2020.
8. Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends 2020;14(March 1(1)):69–71 PubMed PMID: 31996494. Epub 2020/01/31. eng.
9. Cruz-Topete D, Cidliowski JA. One hormone, two actions: anti- and pro-inflammatory effects of glucocorticoids. Neuroimmunomodul 2015;22(1-2):20–32 PubMed PMID: 25227506. Pubmed Central PMCID: PMC4341162. Epub 2014/09/18. eng.
10. Yam IC-C, Lau AC-W, Lai FY-L, Shung E, Chan J, Wong V, et al. Corticosteroid treatment of severe acute respiratory syndrome in Hong Kong. J Infect 2007;54(1):28–39 PubMed PMID: 16542729. Epub 2006/03/15. eng.
11. Arabi YM, Mandourah Y, Al-Hameed F, Siddi AA, Almekhlafi GA, Hussein MA, et al. Corticosteroid therapy for critically ill patients with middle east respiratory syndrome. Am J Respir Crit Care Med 2018;197(6):757–67 PubMed PMID: 29161166. eng.
12. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25(September(9)):603–5 PubMed PMID: 20652370. Epub 2010/07/24. eng.
13. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020:20201585 PubMed PMID: 32031570. eng.
14. Allafar SH, Al-Tawfiq JA, Assiri AY, Alzahrani NA, Alanazi AA, Memish ZA. Clinical predictors of mortality of middle east respiratory syndrome coronavirus (mer-s-cov) infection: a cohort study. Travel Med Infect Dis May-Jun 2019;29:48–50 PubMed PMID: 30872071. Epub 2019/03/11. eng.
15. Jia WD, Deng XL, Tang XP, Yin CB, Zhang FC, Yang Z, et al. [Dose of glucocorticosteroids in the treatment of severe acute respiratory syndrome]. J Southern Medical University 2009;29(November(11)):2284–7 PubMed PMID: 19923088. Epub 2009/11/20. chi.

16. Chen R-C, Tang X-P, Tan S-Y, Liang B-L, Wan Z-Y, Fang J-Q, et al. Treatment of severe acute respiratory syndrome with glucocorticosteroids: the Guangzhou experience. Chest 2006;129(6):1441–52 PubMed PMID: 16778260. eng.

17. Xu Y, Zhou L, Xu M. [Analysis of corticosteroid therapy in 453 patients with SARS]. Chin J Hospital Pharm 2005(02):58–9.

18. Wang P, Li MY, Shi YL, Wang SX, Liu GF. [Evaluating the effects of different treatments on severe acute respiratory syndrome]. Shanxi Med J 2005(04):270–2.

19. Ding K, Xu ZJ, Huang H, Wang Z, Xu LL, Tong ZH, et al. [Retrospective analysis of the glucocorticoid treatment in 409 patients with severe acute respiratory syndrome]. Chin J General Pract 2005(01):193–4.

20. Auyeung TW, Lee JSW, Lai WK, Choi CH, Lee HK, Lee JS, et al. The use of corticosteroid as treatment in SARS was associated with adverse outcomes: a retrospective cohort study. J Infect 2005;51(2):98–102 PubMed PMID: 16038758. eng.

21. Wang YQ, Wen MH, Chang M, Ding QH, Zeng Y, Meng L, et al. [Investigation of adverse reactions to glucocorticoids in 460 SARS patients]. Adv Drug React J 2004(02):78–82.

22. Wang R, Zhou XQ, Dong J, Wei R, Cao XT, Zhou YC, et al. [Effects and adverse drug reactions of misonidazole in the treatment of patients with severe acute respiratory syndrome]. Chin J Clin Pharmacol Therap 2004(09):992–6.

23. Qin YY. [A clinical investigation in 83 cases with severe acute respiratory syndrome]. Chin J Respir Crit Care Med 2003(04):15–17.

24. He R, Liu Z, Duan XJ. [Adverse effects associated with corticosteroids therapy in 57 SARS case]. Adv Drug React J 2003(06):374–7.

25. Russell CD, Millar JE, Bailie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet (London, England) 2020;395(February 15(10221)):473–5 PubMed PMID: 32043983. Epub 2020/02/12. eng.

26. Shang L, Zhao J, Hu Y, Du R, Cao B. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet (London, England) 2020;395(February 29(10225)):683–4 PubMed PMID: 32122468. Epub 2020/03/04. eng.

27. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet Respiratory medicine 2020 February 18 PubMed PMID: 32085846. Epub 2020/02/23. eng.

28. Montón C, Ewig S, Torres A, El-Ebiary M, Filella X, Rañé A, et al. Role of glucocorticoids on inflammatory response in nonimmunosuppressed patients with pneumonia: a pilot study. Eur Respir J 1999;14(July(1)):218–20 PubMed PMID: 10489855. Epub 1999/09/18. eng.

29. Gonzalo JA, González-García A, Martínez C, Kroemer G. Glucocorticoid-mediated control of the activation and clonal deletion of peripheral T cells in vivo. J Exp Med 1993;177(May 15(5)):1239–46 PubMed PMID: 8478606. Pubmed Central PMCID: PMC219024. Epub 1993/05/01. eng.

30. Wilkinson TM, Li CK, Chui CS, Huang AK, Perkins M, Liebner JC, et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med 2012;18(January 29(2)):274–80 PubMed PMID: 22286307. Epub 2012/01/31. eng.

31. Lee N, Allen Chan KC, Hui DS, Ng EKO, Wu A, Chiu RWK, et al. Effects of early corticosteroid treatment on plasma SARS-associated coronavirus RNA concentrations in adult patients. J Clin Virol 2004;31(4):304–9 PubMed PMID: 15494274. eng.

32. Ling Y, Xu S-B, Liu Y-X, Tian D, Zhu Z-Q, Dai F-H, et al. Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients. Chin Med J (Engl) 2020 10.1097/CM9.0000000000000774. PubMed PMID: 32118631. eng.

33. Stockman UJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med 2006;3(September(9)):e343 PubMed PMID: 16968120. Pubmed Central PMCID: PMC1564166. Epub 2006/09/14. eng.

34. Ni Y-N, Chen G, Sun J, Liang B-M, Liang Z-A. The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis. Crit Care 2019;23(1):99. PubMed PMID: 30917856. eng.

35. Zhao R, Wang H, Wang X, Feng F. Steroid therapy and the risk of osteonecrosis in SARS patients: a dose-response meta-analysis. Osteoporosis Int 2017;28(March(3)):1027–34 PubMed PMID: 27844132. Epub 2016/11/16. eng.